vs
Side-by-side financial comparison of GENMAB A/S (GMAB) and NOVO NORDISK A S (NVO). Click either name above to swap in a different company.
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, Genmab K.K. in Tokyo, Japan, Genmab Germany GmbH in München, Germany and Genmab (Suzhou) Co., Ltd. in Suzhou, China. Genmab is listed on the Co...
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $925.0M | — | ||
| Q2 24 | $779.0M | — | ||
| Q2 23 | $604.5M | — | ||
| Q2 22 | $458.5M | — |
| Q2 25 | $336.0M | — | ||
| Q2 24 | $203.0M | — | ||
| Q2 23 | $193.6M | — | ||
| Q2 22 | $274.2M | — |
| Q2 25 | 93.8% | — | ||
| Q2 24 | 96.4% | — | ||
| Q2 23 | 99.5% | — | ||
| Q2 22 | — | — |
| Q2 25 | 38.9% | — | ||
| Q2 24 | 30.3% | — | ||
| Q2 23 | 35.2% | — | ||
| Q2 22 | 39.4% | — |
| Q2 25 | 36.3% | — | ||
| Q2 24 | 26.1% | — | ||
| Q2 23 | 32.0% | — | ||
| Q2 22 | 59.8% | — |
| Q2 25 | $5.42 | — | ||
| Q2 24 | $3.13 | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
